David A. Siegel Celldex Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 14,400 shares of CLDX stock, worth $532,944. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,400Holding current value
$532,944% of portfolio
0.0%Shares
19 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
61.2MCall Options Held
291KPut Options Held
246K-
Wellington Management Group LLP Boston, MA7.65MShares$283 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.51MShares$167 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.65MShares$135 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.12MShares$115 Million2.11% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$114 Million0.02% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.73B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...